A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.

Trial Profile

A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2015

At a glance

  • Drugs Ipilimumab (Primary) ; Fotemustine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms NIBIT-M1
  • Most Recent Events

    • 12 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 31 Jul 2012 Bristol-Myers Squibb as sponsor and lead trial centre added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Planned End Date 1 May 2013 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top